Akero Therapeutics, Inc. AKRO
Set alert
54.65 USD 0.00 0.00%
At close · Dec 9
54.69 +0.04 +0.07%
After hours · Dec 9, 4:00 PM ET
54.52 Day range 54.65
53.69 52-week range 54.83
- YTD
- +96.44%
- 1 year
- +75.67%
- Open
- 54.52
- Prev close
- 54.65
- Mkt cap
- 4.50B
- Vol
- 11.61M
- Avg vol
- 2.29M
- EPS
- -1.94
- P/E
- -29.54
- Div yield
- 0.00%
More statistics
- Low
- 54.52
- High
- 54.65
- Beta
- -0.40
- Inst. own
- 112.47%
- Dividend
- 0.00
2Y chart
Events in this range
- Aug 9, 2024Earnings: -0.81; estimate -0.9; surprise 10%
- Nov 8, 2024Earnings: -1.05; estimate -0.9; surprise -16.67%
- Feb 28, 2025Earnings: -0.99; estimate -0.98; surprise -1.02%
- May 12, 2025Earnings: 0.9; estimate -1.01; surprise 189.11%
- May 27, 2025Rating: B of A Securities · Buy → Buy
- Aug 4, 2025Rating: TD Cowen · — → Buy
- Aug 8, 2025Earnings: -0.86; estimate -0.97; surprise 11.34%
- Oct 9, 2025Downgrade: Canaccord Genuity · Buy → Hold
- Oct 9, 2025Downgrade: Jefferies · Buy → Hold
- Oct 10, 2025Downgrade: HC Wainwright & Co. · Buy → Neutral
- Oct 10, 2025Downgrade: Wolfe Research · Outperform → Peer Perform
- Nov 7, 2025Earnings: -0.99; estimate -0.94; surprise -5.32%
Signals (78)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Dec 3, 2025 | 11 months ago |
| RSI: Overbought | Oct 30, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 29, 2025 | 1 year ago |
| RSI: Overbought | Oct 17, 2025 | 1 year ago |
| SMA: Bullish | Oct 9, 2025 | 1 year ago |
| RSI: Overbought | Oct 9, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 26, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 18, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Sep 11, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 25, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 22, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 18, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 15, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 7, 2025 | 1 year ago |
| SMA: Bullish | Aug 6, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 6, 2025 | 1 year ago |
| SMA: Bearish | Jul 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| RSI: Overbought | Jun 6, 2025 | 1 year ago |
| SMA: Bullish | May 20, 2025 | 1 year ago |
| MACD: Buy Signal | May 20, 2025 | 1 year ago |
| MACD: Sell Signal | May 13, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| SMA: Bullish | May 7, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | Apr 29, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| SMA: Bearish | Mar 26, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 12, 2025 | 1 year ago |
| SMA: Bullish | Jan 27, 2025 | 1 year ago |
| RSI: Overbought | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 22, 2025 | 1 year ago |
| SMA: Bearish | Jan 10, 2025 | 1 year ago |
| RSI: Oversold | Jan 10, 2025 | 1 year ago |
| SMA: Bearish | Dec 10, 2024 | 1 year ago |
| SMA: Bullish | Dec 6, 2024 | 1 year ago |
| SMA: Bearish | Dec 5, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 15, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 13, 2024 | 1 year ago |
| RSI: Overbought | Nov 6, 2024 | 1 year ago |
| MACD: Buy Signal | Oct 30, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 23, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 11, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 4, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 18, 2024 | 2 years ago |
| SMA: Bullish | Sep 13, 2024 | 2 years ago |
| SMA: Bearish | Sep 11, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 5, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 20, 2024 | 2 years ago |
| SMA: Bullish | Aug 16, 2024 | 2 years ago |
| SMA: Bearish | Aug 14, 2024 | 2 years ago |
| SMA: Bullish | Aug 13, 2024 | 2 years ago |
| SMA: Bearish | Aug 12, 2024 | 2 years ago |
| SMA: Bullish | Aug 8, 2024 | 2 years ago |
| SMA: Bearish | Aug 7, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 30, 2024 | 2 years ago |
| RSI: Overbought | Jul 15, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 11, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 1, 2024 | 2 years ago |
| RSI: Overbought | Jun 13, 2024 | 2 years ago |
| SMA: Bullish | Jun 6, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 4, 2024 | 2 years ago |
| MACD: Sell Signal | May 24, 2024 | 2 years ago |
| MACD: Buy Signal | May 2, 2024 | 2 years ago |
| RSI: Oversold | Apr 25, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 14, 2024 | 2 years ago |
| RSI: Overbought | Mar 7, 2024 | 2 years ago |
| RSI: Overbought | Mar 4, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 14, 2024 | 2 years ago |
Key statistics
- Market cap
- 4.50B
- Enterprise value
- 4.32B
- Trailing P/E
- -29.54
- PEG ratio
- -131.55
- Price / sales
- 0.00
- Price / book
- 4.68
- Beta
- -0.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -15.33%
Analyst view
Price target (mean) —
Ratings (0m) 12 12 buy · 0 hold · 0 sell
- Strong buy9
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.9333.
Financials — quick view
AKRO Revenue — quarterly 0
AKRO Net income — quarterly -81.57M
AKRO EPS — quarterly -0.99
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2025 | Sep 30, 2025 | -0.94 | -0.99 | -0.05 | -5.32% |
| Aug 8, 2025 | Jun 30, 2025 | -0.97 | -0.86 | +0.11 | +11.34% |
| May 12, 2025 | Mar 31, 2025 | -1.01 | 0.90 | +1.91 | +189.11% |
| Feb 28, 2025 | Dec 31, 2024 | -0.98 | -0.99 | -0.01 | -1.02% |
| Nov 8, 2024 | Sep 30, 2024 | -0.90 | -1.05 | -0.15 | -16.67% |
| Aug 9, 2024 | Jun 30, 2024 | -0.90 | -0.81 | +0.09 | +10.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 10, 2025 | Wolfe Research | down | Outperform | Peer Perform |
| Oct 10, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 9, 2025 | Jefferies | down | Buy | Hold |
| Oct 9, 2025 | Canaccord Genuity | down | Buy | Hold |
| Aug 4, 2025 | TD Cowen | init | — | Buy |
| May 27, 2025 | B of A Securities | main | Buy | Buy |
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 69
- Website
- akerotx.com
News
- NextCure To Merge With Avere Therapuetics In All-Stock Deal; NXTC Holders To Receive A Contingent Value Right For 90% Of Net Proceeds From Any Future License, Divestiture Or Monetization Of Its Pipeline Assets And Programs For Two Years; NXTC Also Announces $320M Private Placement
- Bourgeon Capital Management LLC Takes Position in Akero Therapeutics, Inc. $AKRO
- Corient Private Wealth LLC Takes $3.93 Million Position in Akero Therapeutics, Inc. $AKRO
- Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO
- Novo Nordisk has completed its acquisition of Akero Therapeutics
- Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
- Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
- Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
- Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
- Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
Your note
Sign in to keep a note on AKRO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHENG ANDREW | Chief Executive Officer | Stock Gift | Nov 19, 2025 | 436,837 |
| GANGLOFF SCOTT A. | Chief Technology Officer | Conversion of Exercise of derivative security | Aug 14, 2025 | 26,351 |
| GRAHAM G. WALMSLEY | Director | Conversion of Exercise of derivative security | Oct 7, 2025 | 1,293,000 |
| HENDERSON JANE | Director | Conversion of Exercise of derivative security | Aug 11, 2025 | 9,398 |
| IWICKI MARK T. | Director | Stock Award(Grant) | Jun 2, 2025 | 9,398 |
| LAMY PATRICK D | Officer | Sale | Jun 30, 2025 | 29,891 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| HHG PLC | 8.42% | 6,738,556 | 0 | Jun 29, 2025 |
| BlackRock Inc | 7.23% | 5,779,412 | 0 | Jun 29, 2025 |
| General Atlantic Llc | 7.17% | 5,733,989 | 0 | Jun 29, 2025 |
| RTW INVESTMENTS, LLC | 6.85% | 5,477,561 | 0 | Jun 29, 2025 |
| Vanguard Group Inc | 5.66% | 4,529,628 | 0 | Jun 29, 2025 |
| T. Rowe Price Associates, Inc. | 5.64% | 4,509,325 | 0 | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 3.01% | 2,411,506 | 0 | Jul 30, 2025 |
| iShares Russell 2000 ETF | 2.11% | 1,684,321 | 0 | Aug 30, 2025 |
| US Small-Cap Growth II Equity Comp | 2.03% | 1,626,094 | 0 | Jun 29, 2025 |
| Janus Henderson Global Life Sciences | 1.80% | 1,436,176 | 0 | Jun 29, 2025 |
| Janus Henderson Global Life Sciences D | 1.80% | 1,436,176 | 0 | Jun 29, 2025 |
| T. Rowe Price New Horizons | 1.68% | 1,340,893 | 0 | Jul 30, 2025 |